scholarly journals Association between TNF-ɑ-308G/A polymorphism and esophageal cancer risk: An updated meta-analysis and trial sequential analysis

2019 ◽  
Vol 10 (5) ◽  
pp. 1086-1096 ◽  
Author(s):  
Fengming Yang ◽  
Ke Wei ◽  
Zhiqiang Qin ◽  
Chuchu Shao ◽  
Yongqian Shu ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Cancer Risk ◽  
Sequential Analysis ◽  
Meta Analysis ◽  
Trial Sequential Analysis

scholarly journals Lack of association between NAT2 polymorphism and prostate cancer risk: a meta-analysis and trial sequential analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (34) ◽  
pp. 57440-57450 ◽  
Author(s):  
Feng Wang ◽  
Zhiqiang Qin ◽  
Shuhui Si ◽  
Jingyuan Tang ◽  
Lingyan Xu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Sequential Analysis ◽  
Meta Analysis ◽  
Prostate Cancer Risk ◽  
Trial Sequential Analysis ◽  
Nat2 Polymorphism

scholarly journals Impact of LMP7 (rs2071543) gene polymorphism in increasing cancer risk: evidence from a meta-analysis and trial sequential analysis

Oncotarget ◽  
2017 ◽  
Vol 9 (5) ◽  
pp. 6572-6585
Author(s):  
Raju K. Mandal ◽  
Sajad A. Dar ◽  
Arshad Jawed ◽  
Mohd Wahid ◽  
Mohtashim Lohani ◽  
...  
Keyword(s):  
Cancer Risk ◽  
Gene Polymorphism ◽  
Sequential Analysis ◽  
Meta Analysis ◽  
Trial Sequential Analysis

scholarly journals Association between Cyclin D1 G870A (rs9344) polymorphism and cancer risk in Indian population: meta-analysis and trial sequential analysis

2018 ◽  
Vol 38 (6) ◽  
Author(s):  
Nisha Thakur ◽  
Suchitra Kumari ◽  
Ravi Mehrotra
Keyword(s):  
Colorectal Cancer ◽  
Cervical Cancer ◽  
Cancer Risk ◽  
Sequential Analysis ◽  
Indian Population ◽  
Meta Analysis ◽  
Recessive Model ◽  
Trial Sequential Analysis ◽  
Dominant Model ◽  
Allelic Model

Introduction: Association between Cyclin D1 (CCND1) single nucleotide polymorphism (SNP) rs9344 and cancer risk is paradoxical. Thus, we performed a meta-analysis to explore the association between CCND1 variant and overall cancer risk in Indian population. Methods: Data from 12 published studies including 3739 subjects were collected using Pubmed and Embase. RevMan (Review Manager) 5.3 was used to perform the meta-analysis. OR with 95%CI were calculated to establish the association. Results: Overall, the cumulative findings demonstrated that CCND1 polymorphism (rs9344) was not significantly associated with cancer risk in all the genetic models studied (dominant model: GG vs GA+AA: OR (95%CI) = 0.81 (0.60–1.09), P=0.17; recessive model: GG+GA vs AA: OR (95%CI) = 1.23 (0.96–1.59), P=0.11; co-dominant model: GG vs AA: OR (95%CI) = 1.35 (0.93–1.97), P=0.12; co-dominant model: (GG vs GA: OR (95%CI) = 1.16 (0.85–1.59), P=0.34; allelic model: A vs G: OR (95%CI) = 1.20 (1.14–2.85), P=0.23; allelic model: G vs A: OR (95%CI) = 0.83 (0.62–1.12), P=0.23). Subgroup analysis according to cancer types presented significant association of CCND1 polymorphism and increased breast cancer risk in dominant model (GG vs GA+AA: OR = 2.75, 95%CI = 1.54–4.90, P=0.0006) and allelic model (G vs A: OR = 1.63, 95%CI = 1.22–2.19, P=0.001). An increased esophageal cancer risk in recessive model (GG+GA vs AA: OR = 1.51, 95%CI = 1.05–2.16, P=0.03) and co-dominant model (GG vs AA: OR = 2.51, 95%CI = 1.10–5.71, P=0.03) was detected. A higher risk for colorectal cancer was detected under both the co-dominant models (GG vs AA: OR = 2.46, 95%CI = 1.34–4.51, P=0.004 and GG vs GA: OR = 1.74, 95%CI = 1.14–2.67, P=0.01). However, in case of cervical cancer risk a non-significant association was reported under the recessive model (GG+GA vs AA: OR = 1.52, 95%CI = 0.60–3.90, P=0.38) with reference to CCND1 polymorphism (rs9344). The trial sequential analysis (TSA) showed that the cumulative Z-curve neither crossed the trial sequential monitoring boundary nor reached the required information size (RIS). Thus, present meta-analysis remained inconclusive due to insufficient evidence. Conclusion:CCND1 polymorphism rs9344 may not have a role in overall cancer susceptibility in Indian population. However, this polymorphism acts as a crucial risk factor for breast, esophageal, and colorectal cancer but not for cervical cancer. Future studies with larger sample size are required to draw a reliable conclusion.

scholarly journals Association of N-acetyltransferase 1 Polymorphism and Bladder Cancer Risk: An Updated Meta-analysis and Trial Sequential Analysis

2017 ◽  
Vol 32 (3) ◽  
pp. 297-304 ◽  
Author(s):  
Zicheng Xu ◽  
Xiao Li ◽  
Zhiqiang Qin ◽  
Jianxin Xue ◽  
Jingyuan Wang ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Risk ◽  
Fixed Effects ◽  
Sequential Analysis ◽  
Meta Analysis ◽  
Systemic Review ◽  
Trial Sequential Analysis ◽  
Type I ◽  
Bladder Cancer Risk ◽  
Increased Risk

Background Individual studies of the association between N-acetyltransferase 1 (NAT1)*10 allele and bladder cancer susceptibility have shown inconclusive results. To derive a more precise estimation of any such relationship, we performed this systemic review and updated meta-analysis based on 17 publications. Methods A total of 17 studies were investigated with 4,322 bladder cancer cases and 4,944 controls. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. Subgroup analyses were conducted based on ethnicity, sex, source of controls and detecting methods. Then trial sequential analysis was performed to evaluate whether the evidence of the results was sufficient and reduce the risk of type I error. Results There was no association between NAT1*10 allele and bladder cancer risk in a random-effects model (OR = 0.96, 95% CI, 0.84-1.10) or in a fixed-effects model (OR = 0.95, 95% CI, 0.87-1.03). In addition, no significantly increased risk of bladder cancer was found in any other subgroup analysis. Then, trial sequential analyses demonstrated that the results of our study need to be further verified. Conclusions Despite its limitations, the results of the present meta-analysis suggested that there was no association between NAT1* 10 allele and bladder cancer risk. More importantly, our findings need to be further validated regarding whether being without the NAT1*10 allele could in the future be shown to be a potential marker for the risk of bladder cancer.

scholarly journals Role of IL-1β rs1143634 (+3954C>T) polymorphism in cancer risk: an updated meta-analysis and trial sequential analysis

2021 ◽  
Vol 49 (12) ◽  
pp. 030006052110601
Author(s):  
Sarah Jafrin ◽  
Md. Abdul Aziz ◽  
Mohammad Safiqul Islam
Keyword(s):  
Cancer Risk ◽  
Sequential Analysis ◽  
Meta Analysis ◽  
Asian Population ◽  
Cancer Development ◽  
Sensitivity Analyses ◽  
Trial Sequential Analysis ◽  
Case Control Studies ◽  
Risk Of Cancer

Objective Oxidative stress caused by the pro-inflammatory cytokine interleukin (IL)-1β has been widely investigated for cancer risk. In this study, we focused on the role of IL-1β rs1143634 polymorphism to reveal its impact on cancer development. Methods Related studies with fixed inclusion criteria were selected from electronic databases to May 2021. This meta-analysis was performed with odds ratios and 95% confidence intervals. Heterogeneity, publication bias and sensitivity analyses were also conducted. Trial sequential analysis (TSA) and in- silico gene expression analysis were performed. Results Forty-four case–control studies involving 18,645 patients with cancer and 22,882 controls were included. We observed a significant association of this single nucleotide polymorphism with overall cancer risk in the codominant model 3 (1.13-fold), recessive model (1.14-fold) and allelic model (1.08-fold). Subgroup analysis revealed that rs1143634 elevated the risk of gastric cancer, breast cancer and multiple myeloma. In addition, Asian and mixed populations and hospital-based controls had a significantly higher risk of cancer development. TSA confirmed our findings. Conclusion Our meta-analysis revealed that the presence of IL-1β rs1143634 polymorphism increases the risk of cancer development. Among polymorphism carriers, the Asian population has a higher risk than other ethnic populations. This meta-analysis was registered retrospectively at INPLASY ( https://inplasy.com/ , INPLASY2021100044).

scholarly journals XRCC2 Arg188His polymorphism and colorectal cancer risk: a meta-analysis

2021 ◽  
Vol 49 (10) ◽  
pp. 030006052110394
Author(s):  
Zhiyu Wang ◽  
Yaning Wei ◽  
Lin An ◽  
Chenglin Xi ◽  
Kunjie Wang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Risk Factor ◽  
Cancer Risk ◽  
Confidence Intervals ◽  
Sequential Analysis ◽  
Meta Analysis ◽  
Pooled Analysis ◽  
Cochrane Library ◽  
Trial Sequential Analysis ◽  
X Ray

Objective To investigate the potential correlation between the Arg188His (rs3218536) polymorphism of X-ray repair cross-complementing 2 ( XRCC2) and colorectal cancer (CRC) risk, as the association remains unclear. Methods The CNKI, PubMed, EMBASE and Cochrane library databases were systematically searched for relevant studies published up to July 2021. Data were extracted from included studies, and analysed for pooled or subgroup odds ratios (ORs) with 95% confidence intervals (CIs) using STATA 12.0 software. Results Seven published studies were included. Pooled analysis revealed that the XRCC2 Arg188His polymorphism was associated with increased CRC risk (His versus Arg: OR 1.14, 95% CI 1.01, 1.29). Trial Sequential Analysis to test the power of the results showed that they were unreliable and the meta-analysis required additional studies. Conclusion The current meta-analysis suggests that the XRCC2 Arg188His polymorphism may be a risk factor for CRC.

Sign in / Sign up

Export Citation Format

Share Document